The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Design and Validation of Liposomal ApoE2 Gene Delivery System to Evade Blood–Brain Barrier for Effective Treatment of Alzheimer’s Disease
Open accessAbstract
Targeting gene-based therapeutics to the brain is a strategy actively sought to treat Alzheimer’s disease (AD). Recent findings discovered the role of apolipoprotein E (ApoE) isoforms in the clearance of toxic amyloid beta proteins from the brain. ApoE2 isoform is beneficial for preventing AD development, whereas ApoE4 is a major contributing factor to the disease. In this paper, we demonstrated efficient brain-targeted delivery of ApoE2 encoding plasmid DNA (pApoE2) using glucose transporter-1 (glut-1) targeted liposomes. Liposomes were surface-functionalized with a glut-1 targeting ligand mannose (MAN) and a cell-penetrating peptide (CPP) to enhance brain-targeting and cellular internalization, respectively. Among various CPPs, rabies virus glycoprotein peptide (RVG) or penetratin (Pen) was selected as a cell-penetration enhancer. Dual (RVGMAN and PenMAN)-functionalized liposomes were cytocompatible at 100 nM phospholipid concentration and demonstrated significantly higher expression of ApoE2 in bEnd.3 cells, primary neurons, and astrocytes compared to monofunctionalized and unmodified (plain) liposomes. Dual-modified liposomes also showed ∼2 times higher protein expression than other formulation controls in neurons cultured below the in vitro BBB model. These results translated well to in vivo efficacy study with significantly higher transfection of pApoE2 in the C57BL/6 mice brain following single tail vein administration of RVGMAN and PenMAN functionalized liposomes without any noticeable signs of toxicity. These results illustrate the potential of surface-modified liposomes for safe and brain-targeted delivery of the pApoE2 gene for effective AD therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, while ApoE2 is beneficial for preventing AD development, ApoE4 is a contributing factor to AD progression [101].”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [101]
The cited source says what the claim attributes to it.
In the citing paper
“The results showed that dual-modified liposomes resulted in ∼2 times higher ApoE2 protein expression in the brain of mice compared to endogenous ApoE levels.”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [101]
The cited source says what the claim attributes to it.
In the citing paper
“Plain or monofunctionalized liposomes resulted in ∼1.25 times higher expression than the endogenous one.”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [101]
The cited source says what the claim attributes to it.
In the citing paper
“Arora et al. [101] demonstrated efficient brain-targeted delivery of pApoE2 using GLUT-1-targeted, dual-functionalized liposomes, in in vitro (Transwell BBB model) and in vivo (C57BL/6 mice) studies.”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [101]
The cited source says what the claim attributes to it.
In the citing paper
“Results in vitro showed that dual-functionalized liposomes had 2 times greater transfection efficiency than plain and monofunctionalized liposomes.”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [101]
The cited source says what the claim attributes to it.
In the citing paper
“Following single-tail vein administration, the use of these liposomes to encapsulate the ApoE2/chitosan complex proved to significantly enhance the transport and transfection of the ApoE2 gene across the BBB in in vivo models, without any noticeable signs of toxicity.”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [101]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Danaei, M., Dehghankhold, M., Ataei, S., Davarani, F. H., Javanmard, R., Dokhani, A., Khorasani, S., & Mozafari, M. R. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10020057 · Cited by 4,967
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles
Fröhlich, E. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s36111 · Cited by 2,561
Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes
Klibanov, A. L., Maruyama, K., Torchilin, V. P., & Huang, L. (1990) · FEBS Letters · doi:10.1016/0014-5793(90)81016-h · Cited by 2,030
2018 Alzheimer's disease facts and figures
Alzheimer's Association (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.001 · Cited by 1,912
Alzheimer Mechanisms and Therapeutic Strategies
Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744
Astrocytes induce blood–brain barrier properties in endothelial cells
Janzer, R. C., & RAFF, M. C. (1987) · Nature · doi:10.1038/325253a0 · Cited by 1,613
Research works printed but not linked: 1
- Gardlík R., 2005, Med. Sci. Monit., 11, RA110
Cited by
Sorted by citations
Lamptey, R. N. L., Chaulagain, B., Trivedi, R., Gothwal, A., Layek, B., & Singh, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031851 · Cited by 1,010
Self-citationA Comprehensive Review of Nanoparticles: From Classification to Application and Toxicity
Eker, F., Duman, H., Akdaşçi, E., Bolat, E., Sarıtaş, S., Karav, S., & Witkowska, A. M. (2024) · Molecules · doi:10.3390/molecules29153482 · Cited by 303
Nanomedicine: How nanomaterials are transforming drug delivery, bio-imaging, and diagnosis
Kurul, F., Turkmen, H., Çetin, A. E., & Topkaya, S. N. (2025) · Next Nanotechnology · doi:10.1016/j.nxnano.2024.100129 · Cited by 280
Pires, M., & Rego, A. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24010778 · Cited by 157
Juhairiyah, F., & de Lange, E. C. M. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00648-z · Cited by 164
Teixeira, M. I., Lopes, C. M., Amaral, M. H., & Costa, P. C. (2023) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2022.112999 · Cited by 154
Poudel, P., & Park, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040835 · Cited by 124
Recent advances in using liposomes for delivery of nucleic acid-based therapeutics
Nsairat, H., Alshaer, W., Odeh, F., Esawi, E., Khater, D., Bawab, A. A., El‐Tanani, M., Awidi, A., & Mubarak, M. S. (2023) · OpenNano · doi:10.1016/j.onano.2023.100132 · Cited by 119
Altered Metabolism in Alzheimer Disease Brain: Role of Oxidative Stress
Rummel, N. G., & Butterfield, D. A. (2021) · Antioxidants and Redox Signaling · doi:10.1089/ars.2021.0177 · Cited by 111
Endothelial Dysfunction in Neurodegenerative Diseases
Fang, Y., Hsieh, Y., Hu, C., & Tu, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032909 · Cited by 102
A review of the tortuous path of nonviral gene delivery and recent progress
Sharma, D., Arora, S., Singh, J., & Layek, B. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.05.192 · Cited by 102
Self-citationPeptides as Pharmacological Carriers to the Brain: Promises, Shortcomings and Challenges
Parrasia, S., Szabó, I., Zoratti, M., & Biasutto, L. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00523 · Cited by 95
Enhancing autophagy in Alzheimer's disease through drug repositioning
Eshraghi, M., Ahmadi, M., Afshar, S., Lorzadeh, S., Adlimoghaddam, A., Rezvani Jalal, N., West, R., Dastghaib, S., Igder, S., Torshizi, S. R. N., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108171 · Cited by 89
Levodopa-loaded nanoparticles for the treatment of Parkinson's disease
van Vliet, E. F., Knol, M. J., Schiffelers, R. M., Caiazzo, M., & Fens, M. H. A. M. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.06.026 · Cited by 85
Nanomedicine: A Promising Way to Manage Alzheimer’s Disease
Khan, N. H., Mir, M., Ngowi, E. E., Zafar, U., Khakwani, M. M. A. K., Khattak, S., Zhai, Y., Jiang, E., Zheng, M., Duan, S., et al. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.630055 · Cited by 84
Witika, B. A., Poka, M., Demana, P. H., Matafwali, S. K., Melamane, S., Khamanga, S. M., & Makoni, P. A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040836 · Cited by 85
Duan, L., Li, X., Ji, R., Hao, Z., Kong, M., Wen, X., Guan, F., & Ma, S. (2023) · Polymers · doi:10.3390/polym15092196 · Cited by 83
Khalid-Salako, F. A., Khaligh, S. S., Fathi, F., Demirci, O. C., Öncer, N., Kurt, H., & Yüce, M. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c07366 · Cited by 78
Nanocarrier mediated drug delivery as an impeccable therapeutic approach against Alzheimer’s disease
Taliyan, R., Kakoty, V., Sarathlal, K. C., Kharavtekar, S. S., Karennanavar, C. R., Choudhary, Y. K., Singhvi, G., Riadi, Y., Dubey, S. K., & Kesharwani, P. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.044 · Cited by 79
Advances in dendrimer-mediated targeted drug delivery to the brain
Gauro, R., Nandave, M., Jain, V. K., & Jain, K. (2021) · Journal of Nanoparticle Research · doi:10.1007/s11051-021-05175-8 · Cited by 70
Arora, S., Kanekiyo, T., & Singh, J. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.03.203 · Cited by 73
Self-citationCai, X., Drummond, C. J., Zhai, J., & Tran, N. L. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202404234 · Cited by 75
Liposomes: An emerging carrier for targeting Alzheimer's and Parkinson's diseases
Pandian, S. R. K., Vijayakumar, K. K., Murugesan, S., & Kunjiappan, S. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e09575 · Cited by 77
New Drug Delivery Systems Developed for Brain Targeting
Rawal, S. U., Patel, B. M., & Patel, M. M. (2022) · Drugs · doi:10.1007/s40265-022-01717-z · Cited by 65
Multifunctional Nanotheranostics for Overcoming the Blood–Brain Barrier
Beygi, M. H. M., Oroojalian, F., Azizi‐Arani, S., Hosseini, S. S., Mokhtarzadeh, A., Kesharwani, P., & Sahebkar, A. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202310881 · Cited by 66
Poustforoosh, A., Nematollahi, M. H., Hashemipour, H., & Pardakhty, A. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.02.015 · Cited by 62
Advances on Therapeutic Strategies for Alzheimer’s Disease: From Medicinal Plant to Nanotechnology
Hassan, N. A., Alshamari, A. K., Hassan, A. A., Elharrif, M. G., Alhajri, A. M., Sattam, M., & Khattab, R. R. (2022) · Molecules · doi:10.3390/molecules27154839 · Cited by 68
Mechanistic insights and emerging therapeutic stratagems for Alzheimer’s disease
Rajendran, K., & Krishnan, U. M. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102309 · Cited by 59
Drug delivery strategies with lipid-based nanoparticles for Alzheimer’s disease treatment
Jang, Y.-J., Kang, S.-J., Park, H. S., Lee, D., Kim, J. H., Kim, J.-E., Kim, D., Chung, C., Yoon, J., & Bhang, S. H. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03109-3 · Cited by 64
The application of nanotechnology in treatment of Alzheimer’s disease
Cao, Y., & Zhang, R. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.1042986 · Cited by 54
Susa, F., Arpicco, S., Pirri, C. F., & Limongi, T. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16070849 · Cited by 50
Pirhaghi, M., Mamashli, F., Moosavi-Movahedi, F., Arghavani, P., Amiri, A., Davaeil, B., Mohammad-Zaheri, M., Mousavi-Jarrahi, Z., Sharma, D., Langel, Ü., et al. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c01167 · Cited by 47
Mohapatra, P., Gopikrishnan, M., Doss, C. G. P., & Chandrasekaran, N. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s442520 · Cited by 49
In vitro and in vivo optimization of liposomal nanoparticles based brain targeted vgf gene therapy
Arora, S., & Singh, J. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121095 · Cited by 44
Self-citationExosome-based approaches in the management of Alzheimer’s disease
Kandimalla, R., Saeed, M., Tyagi, N., Gupta, R. C., & Aqil, F. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104974 · Cited by 45
Advancements in the Application of Nanomedicine in Alzheimer’s Disease: A Therapeutic Perspective
Puranik, N., Yadav, D., & Song, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814044 · Cited by 45
Muolokwu, C. E., Chaulagain, B., Gothwal, A., Mahanta, A. K., Tagoe, B., Lamsal, B., & Singh, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1405423 · Cited by 42
Self-citationBrain targeting based nanocarriers loaded with resveratrol in Alzheimer's disease: A review
Jalili, C., Kiani, A., Gholami, M., Bahrehmand, F., Fakhri, S., Kakehbaraei, S., & Kakebaraei, S. (2023) · IET Nanobiotechnology · doi:10.1049/nbt2.12127 · Cited by 43
A Promising Approach: Magnetic Nanosystems for Alzheimer’s Disease Theranostics
Chaparro, C. I. P., Simões, B. T., Borges, J. P., Castanho, M. A. R. B., Soares, P. I. P., & Neves, V. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092316 · Cited by 40
Rufino-Ramos, D., Albuquerque, P. R., Leandro, K., Carmona, V., Martins, I. M., Fernandes, R., Henriques, C., Lobo, D., Faro, R., Perfeito, R., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.04.001 · Cited by 39
Recent Progress in Nanomedicine for the Diagnosis and Treatment of Alzheimer’s Diseases
Yang, H., Tan, H., Wen, H., Xin, P., Liu, Y., Deng, Z., Xu, Y., Gao, F., Zhang, L., Ye, Z., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c11966 · Cited by 37
Luo, Q., Yang, J., Yang, M., Wang, Y., Liu, Y., Liu, J., Kalvakolanu, D. V., Cong, X., Zhang, J., Zhang, L., et al. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101457 · Cited by 41
Nanoliposomes as safe and efficient drug delivery nanovesicles
Fatfat, Z., Karam, M., Maatouk, B. I., Fahs, D., & Gali‐Muhtasib, H. U. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91668-4.00002-2 · Cited by 33
Peptide-functionalized nanoparticles for brain-targeted therapeutics
Tang, S. N., Han, E. L., & Mitchell, M. J. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01840-w · Cited by 39
Next-Generation Drug Delivery for Neurotherapeutics: The Promise of Stimuli-Triggered Nanocarriers
Boyuklieva, R., Zahariev, N., Simeonov, P., Penkov, D., & Katsarov, P. (2025) · Biomedicines · doi:10.3390/biomedicines13061464 · Cited by 36
Kuo, Y., Ng, I.-W., & Rajesh, R. (2021) · Materials Science and Engineering C · doi:10.1016/j.msec.2021.112233 · Cited by 32
Ouyang, J., Jiang, Y., Deng, C., Zhong, Z., & Lan, Q. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s314895 · Cited by 33
Gothwal, A., Lamptey, R. N. L., & Singh, J. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00031 · Cited by 30
Self-citationBio–Nano Toolbox for Precision Alzheimer's Disease Gene Therapy
Liu, Y., Xia, X., Zheng, M., & Shi, B. (2024) · Advanced Materials · doi:10.1002/adma.202314354 · Cited by 31
Kršek, A., Jagodic, A., & Batičić, L. (2024) · Medicina · doi:10.3390/medicina60091384 · Cited by 31
Zhang, M., Xiang, C., Niu, R., He, X., Luo, W., Liu, W., & Gu, R. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00048 · Cited by 34
Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer’s disease?
Vecchio, F. L., Bisceglia, P., Imbimbo, B. P., Lozupone, M., Latino, R. R., Resta, E., Leone, M., Solfrizzi, V., Greco, A., Daniele, A., et al. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221081605 · Cited by 28
Lozupone, M., Imbimbo, B. P., Balducci, C., Vecchio, F. L., Bisceglia, P., Latino, R. R., Leone, M. A., Dibello, V., Solfrizzi, V., Greco, A., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12728 · Cited by 28
Sharma, D., Arora, S., Banerjee, A., & Singh, J. (2021) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2020.102357 · Cited by 29
Self-citationAdvances in Antioxidant Nanomedicines for Imaging and Therapy of Alzheimer's Disease
Hasan, I., Guo, B., Zhang, J., & Chang, C. (2022) · Antioxidants and Redox Signaling · doi:10.1089/ars.2022.0107 · Cited by 25
Brain Targeting Nanomedicines: Pitfalls and Promise
Käkinen, A., Jiang, Y., Davis, T. P., Teesalu, T., & Saarma, M. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s454553 · Cited by 26
Lamptey, R. N. L., Sun, C., Layek, B., & Singh, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032213 · Cited by 24
Self-citationGrosso, C., Silva, A., Delerue-Matos, C. M., & Barroso, M. F. (2023) · Pharmaceuticals · doi:10.3390/ph16121721 · Cited by 26
Apolipoprotein E in Alzheimer’s Disease: Focus on Synaptic Function and Therapeutic Strategy
Qu, L., Xu, S., Lan, Z., Fang, S., Xu, Y., & Zhu, X. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04449-1 · Cited by 22
Nucleic Acid–Based Therapeutics in Orphan Neurological Disorders: Recent Developments
Khorkova, O., Hsiao, J. H., & Wahlestedt, C. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.643681 · Cited by 22
Meng, R., Yang, X., Li, Y., & Zhang, Q. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.059 · Cited by 20
The Different Cellular Entry Routes for Drug Delivery Using Cell Penetrating Peptides
Okafor, M., Schmitt, D. A., Ory, S., Gasman, S., Hureau, C., Faller, P., & Vitale, N. (2025) · Biology of the Cell · doi:10.1111/boc.70012 · Cited by 22
Non-viral approaches for gene therapy and therapeutic genome editing across the blood–brain barrier
Xie, R., Wang, Y., Burger, J. C., Li, D., Zhu, M., & Gong, S. (2023) · Med-X · doi:10.1007/s44258-023-00004-0 · Cited by 22
Nanoliposomes as nonviral vectors in cancer gene therapy
Yildiz, Ş., Entezari, M., Paskeh, M. D. A., Mirzaei, S., Kalbasi, A., Zabolian, A., Hashemi, F., Hushmandi, K., Hashemi, M., Raei, M., et al. (2024) · MedComm · doi:10.1002/mco2.583 · Cited by 18
Rajizadeh, M. A., Motamedy, S., Mir, Y., Akhgarandouz, F., Nematollahi, M. H., & Nezhadi, A. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.105011 · Cited by 17
Zhu, P., Xiao, L., & Wang, Y. (2025) · Fluids and Barriers of the CNS · doi:10.1186/s12987-025-00721-1 · Cited by 19
Gene Therapy: Towards a New Era of Medicine
Bhagat, M., Kamal, R., Sharma, J., Kaur, K., Sharma, A. K., Singh, T. G., Bhatia, R., & Awasthi, A. (2024) · AAPS PharmSciTech · doi:10.1208/s12249-024-03010-6 · Cited by 16
Recent advances in nanomaterial-based brain-targeted delivery systems for glioblastoma therapy
Qu, M., Wang, Q., Wang, X., Tang, J., Dong, X., Zhao, C., & Guan, Q. (2025) · Nanomedicine · doi:10.1080/17435889.2025.2503694 · Cited by 15
Cell-Penetrating Peptides-Mediated Therapeutic Agents Delivery into the Central Nervous System
Wei, Y., Bao, H., Wang, L., Cao, Y., Liu, Z., Zhu, X., Chen, T., Wu, A., & Li, J. (2024) · ACS Materials Letters · doi:10.1021/acsmaterialslett.4c00397 · Cited by 13
Muolokwu, C. E., Gothwal, A., Kanekiyo, T., & Singh, J. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00870 · Cited by 14
Self-citationLamptey, R. N. L., Sun, C., & Singh, J. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.122841 · Cited by 14
Self-citationMolecular imaging-guided diagnosis and treatment integration for brain diseases
Yu, D., Liu, M., Ding, Q., Wu, Y., Wang, T., Song, L., Li, X., Qian, K., Cheng, Z., Gu, M., et al. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.123021 · Cited by 12
Pancholi, B., Choudhary, M. K., Kumar, M., Babu, R., Vora, L. K., Khatri, D. K., & Garabadu, D. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.106816 · Cited by 13
Evolution of lipid nanoparticles as charioteers of Alzheimer's disease therapeutics
Chakraborty, B., Patel, G., Padhan, B., Das, J., & Patel, M. (2024) · Applied Materials Today · doi:10.1016/j.apmt.2024.102442 · Cited by 15
Advancing Nanomaterial-Based Strategies for Alzheimer’s Disease: A Perspective
Zhou, H., Yin, X., Zhang, G., Yang, Z., & Zhou, R. (2025) · JACS Au · doi:10.1021/jacsau.5c00002 · Cited by 15
A Review of Brain-Targeted Nonviral Gene-Based Therapies for the Treatment of Alzheimer’s Disease
Arora, S., Sharma, D., Layek, B., & Singh, J. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00611 · Cited by 11
Self-citationLipid-based Non-viral Vector: Promising Approach for Gene Delivery
Panday, A., Dixena, B., Jain, N. S., & Jain, A. K. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128324084240828084904 · Cited by 9
Sharma, D. K. (2025) · Journal of drug targeting · doi:10.1080/1061186x.2025.2561788 · Cited by 11
Nanomedicine strategies for central nervous system (CNS) diseases
Nagri, S., Rice, O., & Chen, Y. (2023) · Frontiers in Biomaterials Science · doi:10.3389/fbiom.2023.1215384 · Cited by 9
Chaulagain, B., & Singh, J. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00811 · Cited by 10
Self-citationAdvanced intranasal peptide delivery systems for improved management of Alzheimer's disease
Majie, A., Karmakar, V., Ghosh, A., Chakraborty, S., Apurva, A., Layek, B., & Gorain, B. (2025) · Biomaterials Advances · doi:10.1016/j.bioadv.2025.214474 · Cited by 8
Self-citationStress-induced regional characteristics of the blood-brain barrier
Zhou, M.-Y., Xie, F., Zhao, Y. F., Wang, X., Sun, Z., & Qian, L. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111548 · Cited by 8
Nagaraju, P. G., Ashwini, S., & G., P. P. C. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2092446 · Cited by 7
McGuire, T. K., Stasiewicz, M., Woods, I., Dervan, A. G., & O’Brien, F. J. (2023) · Advanced NanoBiomed Research · doi:10.1002/anbr.202300030 · Cited by 8
Sharma, R. K. (2023) · Current Gene Therapy · doi:10.2174/1566523223666230911120922 · Cited by 6
Drug Delivery for Neurological Disorders Using Nanotechnology
Nag, S., Bhatt, M., Ghosh, S., Dey, A., Paul, S., Dutta, S., Mohanto, S., Gowda, B. H. J., & Ahmed, M. G. (2023) · Springer eBooks · doi:10.1007/978-981-99-9510-3_7 · Cited by 6
Nanoparticles as an Encouraging Therapeutic Approach to Alzheimer’s Disease
Batko, J., Antosz, K., Nowakowska, H., Błażejewska, M., Kowalik, E. M., Beszłej, J. A., & Leszek, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167725 · Cited by 5
Extravaganza of Nanobiotechnology in the Diagnosis and Treatment of Dementia Patients
Bhattacharya, S. (2022) · Current Pharmaceutical Biotechnology · doi:10.2174/1385272827666221027103050 · Cited by 6
Roamcharern, N., & Yubolphan, R. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1810486 · Cited by 4
Kuan, W., Alfaidi, M., Horne, C. B., Vallin, B., Fox, S. E., Fazal, S. V., Williams‐Gray, C. H., & Barker, R. A. (2022) · Brain Pathology · doi:10.1111/bpa.13128 · Cited by 6
Controlled Drug Release Systems for Cerebrovascular Diseases
Martín‐Morales, C., Caspani, S., Desco, M., Sousa, C. T., & Gómez‐Gaviro, M. V. (2024) · Advanced Therapeutics · doi:10.1002/adtp.202400239 · Cited by 4
Amatya, R., Min, K. A., & Shin, M. C. (2022) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-022-00566-y · Cited by 4
Panigrahy, S., Sikder, A., Amulya, E., Shah, S., Khairnar, P., Saraf, S., & Srivastava, S. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.105325 · Cited by 5
Nanoformulations targeting Alzheimer's disease
Kapoor, D. U., Sharma, D., Pathak, Y. V., Prajapati, B. G., & Satani, B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13205-6.00010-8 · Cited by 5
Gothwal, A., Muolokwu, C. E., Chaulagain, B., Mahanta, A. K., & Singh, J. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.143542 · Cited by 3
Self-citationBlood–brain barrier and nanovesicles for brain-targeting drug delivery
Omidi, Y., Omidian, H., Kwon, Y., & Castejon, A. M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91865-7.00007-9 · Cited by 3
Rewiring Neuroimmunity: Nanoplatform Innovations for CNS Disease Therapy
Akbar, M. U., Guo, W., Shen, X. M., Fang, Y., Liu, Y., Wang, P., Elnathan, R., & Chen, Y. (2025) · Advanced Therapeutics · doi:10.1002/adtp.202500124 · Cited by 3
Liposomal and Nanomaterial-Based Strategies for Targeted Alzheimer’s Disease Therapy
Balagurusamy, B., Ganesan, V., Gopi, V., & Ilayaperumal, P. (2025) · ACS Omega · doi:10.1021/acsomega.5c05391 · Cited by 4
Functionalized biopolymer-based drug delivery systems: current status and future perspectives
Layek, B. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821437-4.00020-7 · Cited by 3
Self-citationGothwal, A., Lamptey, R. N. L., Trivedi, R., Chaulagain, B., & Singh, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241613019 · Cited by 3
Self-citation
Metadata
- Authors
- Arora, S., Layek, B., & Singh, J.
- Affiliations
- North Dakota State University (US)
- Corresponding author
- Singh, Jagdish
- Venue
- Molecular Pharmaceutics
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-08-11
- Volume
- 18
- Issue
- 2
- Pages
- 714-725
- ISSN
- 1543-8384 (ISSN-L)
- 1543-8392
- PMC
- PMC10292003
- OpenAlex
- W3048402510
- Cited by
- 149
- References
- 86
- Citations by year
- 2026: 18 · 2025: 31 · 2024: 36 · 2023: 25 · 2022: 25 · 2021: 14
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Molecular Pharmaceutics (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Aging (R01AG051574)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- Alzheimer's disease, apolipoprotein E2, gene delivery, liposomes, blood-brain barrier, glucose transporter 1, cell-penetrating peptides, penetratin, plasmid transfection, brain-targeted delivery, amyloid-beta clearance, bEnd.3 cells, astrocytes, in vitro BBB model, in vivo transfection
- MeSH terms
- Alzheimer Disease, Animals, Astrocytes, Blood-Brain Barrier, Brain, Cell Line, Drug Compounding, Female, Humans, Liposomes, Male, Neurons, Gene Transfer Techniques, Models, Animal, Glucose Transporter Type 1, Mice, Rats, Apolipoprotein E2, Cell-Penetrating Peptides, Primary Cell Culture
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
